ProKidney Q1 net loss $38M; cash $328.5M; REGEN-007 data due Q2 2025

PROKIDNEY CORP.

Net loss before noncontrolling interest was $38.0M for Q1 2025 vs $35.3M in Q1 2024.
Cash, cash equivalents and marketable securities totaled $328.5M as of March 31, 2025, funding operations into mid-2027.
Full data from Group 1 of Phase 2 REGEN-007 study expected in Q2 2025 (approx. 20 patients, ~18 months follow-up).
FDA confirmed accelerated approval pathway for rilparencel in Q4 2024; details expected mid-2025 after Type B meeting.
R&D expenses flat at $27.3M; G&A increased to $14.4M from $12.8M in prior-year period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.